Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is demonstrating significant progress in its clinical programs for diabetes and obesity treatments, evidenced by durable glycemic control and a favorable safety profile observed in the COVALENT-111 trial and 52-week Phase II results of icovamenib. The company has also made strides with its investigational oral GLP-1 receptor agonist, BMF-650, which has shown promising preclinical results for weight reduction and appetite suppression. Financially, Biomea reports a reduction in net loss from $32.8 million in Q3 2024 to $16.4 million in Q3 2025, alongside a more than 50% year-over-year decline in operating expenses, indicating a positive trend in financial management and operational efficiency.

Bears say

Biomea Fusion Inc. experienced a significant reduction in research and development (R&D) expenses, decreasing from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may raise concerns about the company's commitment to advancing its clinical programs. General and administrative (G&A) expenses also declined, from $6.8 million to $4.2 million, indicating potential cost-cutting measures that could impact operational capacity. Furthermore, the adjustment in the company's price target from $16.00 to $12.00 reflects a negative reassessment of its financial outlook, suggesting growing apprehensions about its future performance and pipeline viability.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Jan 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.